These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23122819)

  • 1. Azo-reductase activated budesodine prodrugs for colon targeting.
    Marquez Ruiz JF; Kedziora K; O'Reilly M; Maguire J; Keogh B; Windle H; Kelleher DP; Gilmer JF
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7573-7. PubMed ID: 23122819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models.
    Ruiz JF; Kedziora K; Windle H; Kelleher DP; Gilmer JF
    J Pharm Pharmacol; 2011 Jun; 63(6):806-16. PubMed ID: 21585379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors.
    Ruiz JF; Kedziora K; Keogh B; Maguire J; Reilly M; Windle H; Kelleher DP; Gilmer JF
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6636-40. PubMed ID: 21983446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease.
    Ruiz JF; Radics G; Windle H; Serra HO; Simplício AL; Kedziora K; Fallon PG; Kelleher DP; Gilmer JF
    J Med Chem; 2009 May; 52(10):3205-11. PubMed ID: 19397323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azo reductase- activated colon- targeting prodrugs of aminosalicylates for inflammatory bowel disease: preparation, pharmacokinetic and pharmacodynamic profile.
    Suneela D; Gaurav V; Samuel S
    Inflamm Allergy Drug Targets; 2013 Dec; 12(6):419-32. PubMed ID: 24266686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib.
    Marquez Ruiz JF; Kedziora K; Pigott M; Keogh B; Windle H; Gavin J; Kelleher DP; Gilmer JF
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1693-8. PubMed ID: 23416011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis.
    Varshosaz J; Emami J; Tavakoli N; Fassihi A; Minaiyan M; Ahmadi F; Dorkoosh F
    Int J Pharm; 2009 Jan; 365(1-2):69-76. PubMed ID: 18804521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precisely Traceable Drug Delivery of Azoreductase-Responsive Prodrug for Colon Targeting via Multimodal Imaging.
    Zhao XB; Ha W; Gao K; Shi YP
    Anal Chem; 2020 Jul; 92(13):9039-9047. PubMed ID: 32501673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis.
    Nolen H; Fedorak RN; Friend DR
    J Pharm Sci; 1995 Jun; 84(6):677-81. PubMed ID: 7562403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation.
    Sarkate A; Dhaneshwar SS
    World J Gastroenterol; 2017 Feb; 23(7):1147-1162. PubMed ID: 28275295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure requirements for anaerobe processing of azo compounds: implications for prodrug design.
    Gavin J; Ruiz JF; Kedziora K; Windle H; Kelleher DP; Gilmer JF
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7647-52. PubMed ID: 23122822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
    Dhaneshwar SS; Kandpal M; Vadnerkar G; Rathi B; Kadam SS
    Eur J Med Chem; 2007 Jun; 42(6):885-90. PubMed ID: 17258353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats.
    Nolen HW; Fedorak RN; Friend DR
    Biopharm Drug Dispos; 1997 Nov; 18(8):681-95. PubMed ID: 9373725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid.
    Sousa T; Yadav V; Zann V; Borde A; Abrahamsson B; Basit AW
    J Pharm Sci; 2014 Oct; 103(10):3171-5. PubMed ID: 25091594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis.
    Klotz U
    Dig Liver Dis; 2005 Jun; 37(6):381-8. PubMed ID: 15893274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats.
    Ahmadi F; Varshosaz J; Emami J; Tavakoli N; Minaiyan M; Mahzouni P; Dorkoosh F
    Drug Deliv; 2011 Feb; 18(2):122-30. PubMed ID: 20954795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colonic drug delivery: prodrug approach.
    Sinha VR; Kumria R
    Pharm Res; 2001 May; 18(5):557-64. PubMed ID: 11465408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azo chemistry and its potential for colonic delivery.
    Jain A; Gupta Y; Jain SK
    Crit Rev Ther Drug Carrier Syst; 2006; 23(5):349-400. PubMed ID: 17425512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclization-activated prodrugs.
    Gomes P; Vale N; Moreira R
    Molecules; 2007 Nov; 12(11):2484-506. PubMed ID: 18065953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.